Crohn disease is a chronic, inflammatory disease of the gastrointestinal tract. A locus of ∼250 kb at 5q31 (IBD5) 1,2 was previously associated with susceptibility to Crohn disease, as indicated by increased prevalence of a risk haplotype of 11 single-nucleotide polymorphisms 3 among individuals with Crohn disease, but the pathogenic lesion in the region has not yet been identified. We report here that two variants in the organic cation transporter cluster at 5q31 (a missense substitution in SLC22A4 and a G→C transversion in the SLC22A5 promoter) form a haplotype associated with susceptibility to Crohn disease. These variants alter transcription and transporter functions of the organic cation transporters and interact with variants in another gene associated with Crohn disease, CARD15, to increase risk of Crohn disease. These results suggest that SLC22A4, SLC22A5 and CARD15 act in a common pathogenic pathway to cause Crohn disease.
. Consistent with interaction between the IBD5 locus and CARD15 variants associated with Crohn disease 9 , risk for disease was much greater in the presence of both the TC haplotype and the Crohn disease-associated CARD15 alleles ( Table 1) . IBD5 may also be associated with ulcerative colitis 10 , but the TC haplotype did not influence disease risk in 216 individuals with ulcerative colitis that we studied (P = 0.17). Among individuals lacking IBD5 risk haplotypes (i.e., homozygous with respect to the non-risk-associated allele of IGR2078a_1, a surrogate marker for the extended IBD5 haplotype 3, 9 ), 53% of individuals with Crohn disease (n = 99) but only 23% of controls (n = 120) carried at least one 1672T or -207C allele (P = 2 × 10 -6 ). Haplotypes with at least one 1672T or -207C allele on the non-risk-associated IBD5 background were also more frequent in individuals with Crohn disease (0.143, n = 370) than in controls (0.098, n = 246; P = 3.5 × 10 -9 ). By contrast, the haplotype containing the IBD5 risk allele but neither of the 1672T or -207C alleles was almost as frequent among affected individuals as controls (0.012 versus 0.013). These data argue that the SLC22A4 and SLC22A5 1672T and -207C variants per se, rather than other nearby alleles, confer risk for Crohn disease. Although the SLC22A4-SLC22A5 interval has been hypothesized to contain an IBDrelated human ortholog to the mouse gene Slc22a9 (ref. 11), we and others were unable to identify a human Slc22a9 counterpart or any other gene in this region.
SLC22A4 and SLC22A5 are widely expressed [11] [12] [13] [14] , but in situ hybridization data showed that they were specifically expressed in the principal intestinal cell types affected by Crohn disease, including epithelial cells (Fig. 2) , CD68 + macrophages and CD43 + T cells, but not CD20+ B cells (Supplementary Fig. 1 online) . This expression pattern is consistent with the multisystem nature of Crohn disease and involvement of these genes in susceptibility to Crohn disease.
SLC22A4 and SLC22A5 encode the polytopic transmembrane sodium-dependent carnitine and sodium-independent organic cation transporters OCTN1 and OCTN2 (ref. 4) . The L503F substitution in OCTN1 maps to a region (the 11th transmembrane domain) required for transport function 15, 16 and may therefore alter this activity. We investigated OCTN1 function in fibroblasts and found carnitine uptake to be 2.7 times lower in cells expressing 503F than in those expressing 503L (Fig. 3a) . 503F and 503L variants transport carnitine in sodium-and concentration-dependent fashions (Fig. 3c,d ), the 503F variant had a lower V max and higher K m for carnitine uptake (Fig. 3d) . Although the 503F and 503L variants also transported tetraethyl ammonium (TEA) in a sodium-independent but pH-dependent manner (Fig.  3g) , the 503F variant was associated with 3.7 times greater TEA uptake (Fig. 3e) and a higher V max and lower K m for TEA uptake (Fig. 3h) . We observed similar effects in HeLa cells and OCTN2-deficient fibroblasts (Fig. 3b,f) . OCTN1 was previously characterized as a low-affinity carnitine transporter 17 , but this conclusion was based on analysis of the 503F variant rather than the more prevalent wild-type 503L variant, shown here to be a better carnitine transporter. The 503F variant also had less affinity for carnitine and other endogenous substrates but greater affinity for TEA and various xenobiotics (Table 2) than the wild-type 503L variant. Collectively, these results confirm that the L503F substitution substantially alters OCTN1 function.
The -207G→C substitution in SLC22A5 occurs within a heatshock transcription factor (HSF)-binding element (HSE) 18, 19 . We therefore used gel shift assays to evaluate inducible HSF binding to the SLC22A5 HSE. We found that a radioactively labeled oligonucleotide corresponding to the -207G (wild-type) HSE formed high-molecular-weight complexes with nuclear extracts from heatshocked or arachidonic acid-stimulated cells. We also found that mobilities of these complexes were supershifted by antibody to HSF1 but not by antibody to HSF2 (Fig. 4) . In contrast, an oligonucleotide corresponding to the -207C (Crohn disease-associated) HSE formed no complexes. Like nonspecific oligonucleotides, unlabeled competitor -207C oligonucleotide had no effect on -207G binding activity (Fig. 4a) .
We also examined effects of the -207C variant on HSF-induced SLC22A5 transcriptional activation using a luciferase reporter driven by a SLC22A5 promoter segment containing either -207C or -207G. Increases in promoter activity evoked by HSF were significantly greater in OCTN2-deficient fibroblasts expressing -207G than in those expressing -207C (heat-shocked cells, 2.3 times higher; arachidonic acid-stimulated cells, 1.7 times higher; Fig. 4c ). Increases in promoter activity evoked by HSF were also significantly greater in HeLa cells expressing -207G than in those expressing -207C (2.2 times higher, P = 0.0001; data not shown). These results suggest that the -207C variant disrupts a functional promoter element. The data reported here identify variants of SLC22A4 and SLC22A5 that increase susceptibility to Crohn disease. Our data and a previous study of rheumatoid arthritis 20 suggest that these genes have a role in chronic inflammatory disorders. These variants may cause disease by impairing OCTN activity or expression, reducing carnitine transport in a cell-type and disease-specific manner. Defects in oxygen burst-mediated pathogen killing or impaired fatty acid β-oxidation in intestinal epithelium may ensue, the latter of which is exacerbated by bacterial metabolites and causes colitis in experimental models 21, 22 . Alternatively, the effects of the 503F variant on OCTN1 transporter specificity may also diminish uptake of physiologic compounds while increasing uptake of potential toxins, such as putrescine, derived from bacterial catabolism. In either scenario, a role for OCTNs in handling enteric bacteria or their byproducts is consistent with the putative effects of CARD15 mutations on cellular responses to bacterial products and provides a basis for the genetic interaction between these loci.
The L503F substitution probably has modest effects on OCTN1 function, perhaps substantial only under metabolic stress conditions. The SLC22A5 promoter variant and the intronic variant in SLC22A4 associated with rheumatoid arthritis 20 probably become important only after relevant transcription factor activation. Also, as observed for genes associated with other complex diseases 23, 24 , the OCTN variants are prevalent in the general population. These observations do not, however, mitigate their potential pathogenicity. The strong interaction between SLC22A4, SLC22A5 and CARD15 in Crohn disease and the suggested interaction between SLC22A4 and RUNX1 in rheumatoid arthritis suggest that OCTNs participate in multiple pathways underlying chronic inflammation. Our discovery provides a basis for diagnostic tests for Crohn disease risk and identifies the OCTNs as potential targets for therapeutic interventions.
METHODS
We recruited unrelated individuals of European origin as described 1 . Replication cases were an independent cohort from the same center. We randomly selected healthy controls of European descent (average age 26 years) from 1,000 anonymous samples. We obtained ethics approval from the University of Toronto and informed consent from all subjects. Genotyping was done by single base extension (Beckman Coulter SNPstream) or allelespecific PCR 25 . Primer sequences are available on request. We determined haplotype frequencies through maximum likelihood estimation and the dose effect by a likelihood ratio test.
We transfected SLC22A4 (1672C or 1672T) cDNAs into HeLa, GM 10665 or HEK293 fibroblasts using lipofectamine and evaluated them for carnitine or TEA uptake (in triplicate) in transport buffer (pH 8.5 or 6.0) in which NaCl was replaced isotonically with N-methyl-D-glucamine. We determined kinetics and K i values for SLC22A4 transport and inhibition in stably transfected HEK293 by subtracting background uptake (5 mM quinidine).
We used digoxigenin-UTP-labeled sense or antisense riboprobes for wholemount in situ hybridizations as described 26 . We used antibodies to digoxigenin conjugated with alkaline phosphatase to detect hybridized probes. We counterstained sections with Fast Nuclear Red (Dako). We used monoclonal antibodies (Dako) against cytokeratin AE1/AE3 (1:100), CD20 (1:500), CD42 (1:400) and CD68 (1:100) for immunostaining.
For gel shift assays, we took nuclear extracts (10 µg) from HeLa cells, left some untreated, heat-shocked some at 42 °C for 2 h and incubated some with 20 µM arachidonic acid for 30 min. We incubated nuclear extracts with 32 P-labeled or unlabeled (100×) oligonucleotides (SLC22A5 nucleotides -199 to -223 or HSP70 HSEs 27 ). For supershifts, we used antibodies to HSF1 or HSF2 (SantaCruz).
We transfected the SLC22A5 promoter regions (-2.7 kb from ATG) carrying -207C or -207G alleles in the pRL-null reporter vector (Promega) into HeLa or GM10665 cells. After 24 h, we subjected cells heat shock at 42 °C for 2 h or incubated them with 20 µM arachidonic acid for 30 min and assayed them for luciferase activity after 18 h. VOLUME 36 | NUMBER 5 | MAY 2004 NATURE GENETICS 
